| Literature DB >> 31729243 |
Xiao-Sen Li1,2, Ji-Na Wu1,2, Long Yan1,2, Zhong-Fang Xing1,2, Chang-Cai Liu1,2, Bo Chen1,2, Ling Yuan1,2, Yang Yang1,2.
Abstract
Organophosphorus nerve agents inhibit the cholinesterase activity by phosphylation of the active site serine. The resulting phosphylated cholinesterase and adducts on human serum albumin (HSA) are appropriate biomarkers for nerve agents exposure. Several methods have been developed for the detection of nerve agents, including fluoride reactivation or alkaline cleavage. It was previously thought that some nerve agents adducts to HSA could not be detected via fluoride regeneration. In our study, the results showed that tabun (GA) adducts of HSA could be detected by fluoride regeneration. The sample preparation included acetone precipitation, washing and SPE. Deuterated tabun (d5-GA) was applied as the internal standard. The product of regenerated fluorotabun is detected with a good linearity (R2 > 0.997) in the concentration range from 0.02 to 100.0 ng/ml, small relative standard deviation (≤6.89%) and favorable recoveries between 94.8 and 106.3%. The established preparation confirmed the fluorotabun was regenerated from the GA-HSA adducts.Entities:
Keywords: GC–MS/MS; HSA adducts; acetone precipitation; fluoride reactivation; isotope dilution; tabun
Mesh:
Substances:
Year: 2019 PMID: 31729243 PMCID: PMC6923783 DOI: 10.4155/bio-2019-0161
Source DB: PubMed Journal: Bioanalysis ISSN: 1757-6180 Impact factor: 2.681
Figure 1.Generalized fragmentation pathway of tabun.
The optimized selected reaction monitoring transitions parameters for the GC–MS/MS analysis of targets.
| Analytes | Transition ions | Collision energy (V) | Retention times | |
|---|---|---|---|---|
| GA | Quantitation transitions | 5 | 10.46 min | |
| Confirmation transitions | 8 | |||
| FGA | Quantitation transitions | 4 | 6.97 min | |
| Confirmation transitions | 8 | |||
| DGA | Quantitation transitions | 5 | 10.39 min | |
| Confirmation transitions | 14 | |||
DGA: Deuterated tabun; FGA: Fluorotabun; GA: Tabun.
Figure 2.Mass spectrum for the GA, FGA and DGA.
Chemical structures and product ion mass spectra of the precursor ions of (A) GA (m/z 162), (B) FGA (m/z 155) and (C) DGA (m/z 167). Spectra were collected at electron energy of 70 eV over the mass range m/z 33–550. Those fragment ions monitored by SRM are labeled with m/z values in structures.
DGA: Deuterated tabun; FGA: Fluorotabun; GA: Tabun; SRM: Selected reaction monitoring.
Figure 3.GC–MS/MS selected reaction monitoring chromatogram comparison of the residue of tabun (in the 20 ng/ml tabun–human serum albumin adducts) in the matrix after acetone precipitation and three washing steps.
The sample after the first washing is indicated by the black line, and the samples after the second and third washing are indicated by red and blue lines, respectively.
Figure 4.Comparison of tabun-spiked human serum albumin concentration using fluorotabun to deuterated tabun ratios to tabun-spiked concentration.
Figure 5.GC–MS/MS selected reaction monitoring chromatogram comparison of 100.0 and 0.02 ng/ml tabun-spiked human serum albumin samples and blank samples.
GA: Tabun; HSA: Human serum albumin.
The standard curve of tabun and fluorotabun with the calculated concentration, accuracy and precision of quality control samples for the detection of fluorotabun.
| Analytes | Linear range | Linear equation | R2 | ||||
|---|---|---|---|---|---|---|---|
| Sample ID | Theoretical concentration (ng/ml) | Intraday (n = 5) | Calculated concentration (ng/ml) | Accuracy (%) | RSD (%) | ||
| Calculated concentration (ng/ml) | Accuracy (%) | RSD (%) | |||||
| QCL | 0.02 | 0.02 ± 0.003 | 105 | 5.64 | 0.02 ± 0.004 | 106.3 | 5.88 |
| QCM | 20.0 | 19.0 ± 1.8 | 94.8 | 3.52 | 19.4 ± 1.4 | 97.2 | 4.64 |
| QCH | 80.0 | 81.8 ± 2.1 | 102.3 | 5.22 | 84.3 ± 2.9 | 105.4 | 6.89 |
FGA: Fluorotabun; GA: Tabun; QCH: Quality control high; QCL: Quality control low; QCM: Quality control medium; RSD: Relative standard deviation.
Figure 6.GC–MS/MS selected reaction monitoring chromatogram of samples 301–306 in the Organisation for the Prohibition of Chemical Weapons’s 3rd Biomedical Proficiency Testing.